

AIDSVu and HepVu: Visualizing HIV and HCV To End The Epidemics

Heather Bradley, Ph.D.

Assistant Professor of Epidemiology, Georgia State University

Project Director, HepVu

CONFLICT OF INTEREST DISCLOSURE HEATHER BRADLEY, Ph.D.

No financial or commercial interests to disclose





AN INTRODUCTION TO Vu: AIDSVu AND HepVu



AIDSVu and HepVu Mission

Making data widely available, easily accessible and locally relevant to inform public health decision-making




Presented by the Rollins School of Public Health at Emory
University in partnership with
Gilead Sciences





AIDSVu Overview

- AIDSVu maps state-, county-, and city-level HIV data, including:
 - Prevalence and new diagnoses
 - Mortality
 - PrEP Use
- City and state profiles with HIV statistics
- Deeper Look at HIV in the South, PrEP
- Service locator tool for testing, PrEP and Care




AIDSVu.org



HepVu Overview

- Established in 2017 to present the first standardized state-level estimates of people living with Hepatitis C
- Intersection of the Hepatitis C and opioid epidemics to advance awareness, programs, and policies to address the syndemic
- A few of our HepVu Working Group Advisors:
 - amfAR
 - CDC
 - Massachusetts Department of Health
 - NASTAD
 - NIDA
 - UCSD





THE STATE OF HEPATITIS IN AMERICA



Hepatitis C in America

- Hepatitis C is a leading cause of liver-related morbidity and mortality in America
 - Hepatitis C-related deaths were greater than deaths from 60 other infectious diseases combined in 2013
- An estimated 2.3 million people were living with Hepatitis C between 2013 and 2016
 - Three-fourths were Baby Boomers, or those born between 1945 and 1965
- Hepatitis C and other infectious diseases are often-overlooked consequences of America's opioid crisis
 - Hepatitis C infections have nearly tripled in recent years, with the largest increases among persons under 40, largely due to injection drug use

Eliminating Hepatitis C

- The public health surveillance system for Hepatitis C is **not as robust** as it is for other infectious diseases, such as HIV
- Accurate estimates of the burden of Hepatitis C infection in each state are essential to inform policy, programmatic, and resource planning for elimination strategies



 HepVu is a powerful tool to communicate the Hepatitis C epidemic in a clear and compelling way to inform researchers and public health decision-makers' prevention and care efforts



ACTION PLAN



HepVu DATA AND SITE OVERVIEW





View data at the state-level, including:

- Hepatitis C prevalence estimates (2013-2016)
- Hepatitis C-related mortality data (2016)

Opioid maps:

- Opioid prescription rate (2017)
- Narcotic overdose mortality rate (2013-2016)
- Pain reliever misuse percent (2015-2016)







Hepatitis C Prevalence Estimation Data

- State-level burden of Hepatitis C infection informs policies, resource allocation, advocacy, and elimination efforts
- Prevalence of current infection (RNA)
 - Measured in nationally representative residential survey, National Health and Nutrition Examination Survey (NHANES)
 - In most states, it is challenging to measure directly from diagnoses reported to surveillance
- Statistical models allow combining national NHANES Hepatitis C prevalence with local information to yield state-level results
 - National Vital Statistics System (NVSS) mortality
 - American Community Survey (ACS) population sizes

Original Investigation | Public Health JAMA Network Open

December 21, 2018

Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016

Eli S. Rosenberg, PhD1: Elizabeth M. Rosenthal, MPH1: Eric W. Hall, MPH2: et al

» Author Affiliations | Article Information


JAMA Netw Open. 2018;1(8):e186371. doi:10.1001/jamanetworkopen.2018.6371

Kev Points


Question During 2013 to 2016, what proportion of adults were living with hepatitis C virus (HCV) infection in each US state?

Findings In this survey study, US national HCV prevalence during 2013 to 2016 was 0.93% and varied by jurisdiction between 0.45% and 2.34%. Three of the 10 states with the highest prevalence and 5 of the 9 states with the highest number of HCV infections were in the Appalachian region.


Hepatitis C Prevalence, 2013-2016




Number of People with Hepatitis C, 2013-2016



Opioid Maps







Opioid Prescription Rate

Narcotic Overdose Mortality Rate

Pain Reliever
Misuse
Percent

Comparing Data







State Profiles






NEWS & UPDATES TOOLS & RESOURCES Q

Local Data


View state profiles with Hepatitis C statistics, downloadable charts and local resources.



HOME > LOCAL DATA > WASHINGTON, DC

Local Data: Washington, DC

There are approximately 12,700 people living with Hepatitis C in Washington, DC.







Deeper Look: Opioids

The opioid crisis is one of the greatest public health challenges facing the U.S., causing an unprecedented surge in drug overdose deaths, and fueling the rapid rise in new Hepatitis C infections from injection drug use in communities across the country.

As opioid abuse rates have skyrocketed, new Hepatitis C infections have also increased. Data on HepVu show that an estimated 2.3 million Americans were living with Hepatitis C between 2013 and 2016. Though the majority, or roughly threefourths, of all infections were among Baby Boomers (those born between 1945 and 1965), there has been a spike in new Hepatitis C infections among younger Americans.

The number of new Hepatitis C infections more than tripled from 2010 to 2016, largely reflecting infections due to the rise in injection drug use. This has created a syndemic, in which the opioid and Hepatitis C epidemics are linked - with the burden of Hepatitis C being directly exacerbated by injection drug use.

OPIOID EPIDEMIC **HEPATITIS C IN THE UNITED** 350% **INCREASE HEPATITIS C**





The Opioid Epidemic

In 2017, the U.S. Department of Health and Human Services

(HHS) declared a public health state of emergency due to the opioid epidemic. Opioids are highly addictive and include prescription pain relievers, synthetic compounds such as fentanyl, and illegal drugs such as heroin. From 2002 to 2017, the number of deaths due to opioid abuse have more than quadrupled. The opioid epidemic's growth even contributed to a decrease in annual U.S. life expectancy, which declined to 78.6 years in 2016 primarily due to increases in suicides and opioid-related overdose deaths.

- **Deeper Look: Opioids** page presents an in-depth look at the opioid epidemic's impact on Hepatitis C in the U.S.
- Page includes resources, shareable infographics, related blogs, and a graphic illustrating the syndemic between Hepatitis C and injection drug use as a result of the opioid epidemic



Shareable Resources and Future Research

Share:

- Infographics on Hepatitis B and C, and the opioid syndemic
- Blogs from viral hepatitis and opioid experts

2019:

- 2013-2016 Hepatitis C prevalence estimates, stratified by race, age, and sex
- Additional opioid indicators
- Hepatitis Awareness Month and Testing Day infographics (May)
- Ongoing blog series with experts





QUESTIONS?

Learn more at HepVu.org

- info@hepvu.org
- f HepVu
- @HepVu

Subscribe to our newsletter and blog updates at HepVu.org!

